|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PDAC cell lines derived from primary pancreatic tumors arising spontaneously in Kras<sup>LSL-G12D/+</sup>;Trp53<sup>LSL-R172H/+</sup>;Pdx-1 Cre mice were implanted into syngeneic mice and tumors were focally irradiated using the Small Animal Radiation Research Platform (SARRP).
|
27354473 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genetic ablation of NOS2 significantly prolonged survival and reduced tumor severity in LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) mice.
|
27367029 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Disruption of Acvr1b in LSL-KRAS(G12D);Pdx1-Cre mice accelerated the growth of pancreatic IPMNs compared with LSL-KRAS(G12D);Pdx1-Cre mice, but did not alter growth of pancreatic intraepithelial neoplasias.
|
26408346 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Glypican 3 (GPC3)-CAR T cells efficiently suppressed tumor growth in PDX3 and impressively eradicated tumor cells from PDX1 and PDX2, in which GPC3 proteins were highly expressed.
|
28123387 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that PDX-1 is a putative tumor suppressor in breast cancer.
|
22961564 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PDX-1 promoted HEK 293 and MIA PaCa2 tumor formation in SCID mice as compared with that of control (P < .05).
|
20886630 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ability of PDX1 stable transfectant in tumor formation in xenograft mice was assessed.
|
18477649 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lower levels of PDX-1 were found to be present in the primary tumor, while normal colon tissue failed to express detectable levels of PDX-1.
|
18855980 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The induced pancreatic lesions express Pdx1, a marker for pancreas progenitor cells, and many tumors express markers for both exocrine and endocrine cell lineages, suggesting that the tumors may be derived from progenitor cells.
|
14681205 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HER-2/neu overexpression was demonstrated in 26% (9G6, TAB250, GSF-HER2), 27% (3B5, CB11), 33% (A8010) and 42% (A0485, HercepTest) of the tumors.
|
11208826 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Evidence of amplification or rearrangement of 10 recognized cellular oncogenes (N-ras, mycL1, mycN, myc, H-ras, bcl1, H-stf1, sea, kraS2, and fos) was sought in tumor DNA.
|
8106627 |
1994 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By using oligonucleotides representing each of the three CT boxes of the human insulin (HI) gene enhancer and nuclear extracts from the mouse islet tumor cell lines beta TC3 and alpha TC1, we have identified a beta-cell-specific binding activity as reported for IPF1, which has maximal affinity toward the CT2 box.
|
7937976 |
1994 |